Conflicting estimates of the contribution of biological and assay variability to the total variance of consecutive HIV-1 RNA measurements have been reported (2, 9, 11) . Findings indicate that approximately two-thirds of total variance is due to biological fluctuation and that one third is due to assay variance (2, 5) . The increasing number of multilaboratorybased studies has made differences between laboratories another important issue. A study by Skidmore et al. found high interlaboratory variability, indicating a need for an external quality assurance-quality control system for HIV-1 RNA measurements (15) .
The WIHS HIV-1 RNA viral load data are unique because of the long observation period and the homogeneity of material used for the external standards. This report clarifies the key issues of laboratory differences and systematic fluctuations over time that affect the nonbiological variability component of HIV-1 RNA viral load measurements.
In the WIHS, four laboratories (all certified by the Virology Quality Assurance Laboratory [VQA], Rush Presbyterian/St. Luke's Medical Center, Chicago, Ill.) performed HIV-1 RNA testing using three versions of OTC assays and a common set of HIV-1 RNA external standards. The standard consisted of HIV-1-negative plasma spiked with HIV-1 virus (4, 5) . NASBA assays (0.1-ml input [NASBA 0.1 ml ]; lower detection limit [LDL], Ͼ4,000 copies/ml) were run with sets of 1.5 ϫ 10 6 , 1.5 ϫ 10 5 , and 1.5 ϫ 10 4 (ϳ10 6.18 , 10 5.18 , and 10 4.18 , respectively) HIV-1 RNA copies/ml. The corresponding values for standards for both versions of NucliSens (0.2-ml input; LDL, Ͼ400 copies/ml; and 1.0-ml input; LDL, Ͼ80 copies/ml) were 1 log unit lower. The manufacturer retrained laboratory technicians prior to the distribution of NucliSens with reformulated enzymes (October 1998).
We used the mean square error from a one-way analysis of variance to obtain estimates for the intra-assay variance of the log 10 unit of the absolute copy number for each external standard. We used Bartlett's test to compare variances between labs (14) . To evaluate systematic fluctuations over time, we fit smooth curves to scatter plots of all log-transformed results for each external standard using the S-plus lowess function (6, 16) . P values indicate the statistical significance of the observed nonlinear trends.
Assay format and input volume. Table 1 shows overall means and standard deviations (SD) of the log-transformed results of the external standards for each assay-input volume combination. Observed variability was lowest for NucliSens 1.0 ml and was similar for NASBA 0.1 ml .
In a retrospective analysis of assay run acceptability, we defined run rejection criteria as (i) two results exceeding the target value by more than 2 SD, (ii) one result exceeding the target value by more than 3 SD, or (iii) an R square of Ͻ0.95 (8) . Overall rejection rates were 6% for NASBA 0.1 ml , 3% for NucliSens 0.2 ml , and Ͻ1% for NucliSens 1.0 ml (data not shown).
Fluctuations in HIV concentrations greater than 0.5 log 10 unit have been described as clinically relevant (7, 10, 12, 13) . The NASBA 0.1 ml result was more than Ϯ 0.5 log unit from the target of 10 4.18 copies/ml for 23 of 474 runs (5%) compared to 0 of 178 runs for NucliSens 0.2 ml and 0 of 162 runs for NucliSens 1.0 ml (P Ͻ 0.0001). NucliSens 0.2 ml missed the target of 10 3.18 copies/ml 26 times (15%) compared to 0 times for NucliSens 1.0 ml (P Ͻ 0.0001).
Laboratory differences. There were statistically significant differences in levels of variance between labs for the lowestrange standard of all three assay-input volume combinations and for the highest-range standard for NucliSens 1.0 ml (data not shown).
Variability over time. Table 2 summarizes SD for 6-month time intervals corresponding to WIHS visit windows for each assay-input volume combination and VQA external standard. Within each combination and for all standards, the SD was stable and there were no statistically significant trends except with the lowest-range control value for NucliSens 0.2 ml .
For NASBA 0.1 ml (April 1996 to October 1998), the observed nonlinear trends were statistically significant for all standards (lowest range, P ϭ 0.003 [Fig. 1A ]; middle range, P Ͻ 0.0001 [Fig. 1B] ; highest range, P Ͻ 0.0001 [ Fig. 1C] ). NucliSens 0.2 ml (October 1997 to January 1999) demonstrated a marginally significant trend in the highest-range standard ( Fig. 1F ; P ϭ 0.03). NucliSens 1.0 ml (February 1999 to January 2000) demonstrated significant trends in the middle and highrange standards (Fig. 1H , P ϭ 0.003, and I, P ϭ 0.001, respectively).
While we observed no gain in precision in the transition from NASBA 0.1 ml to Nuclisens 0.2 ml , there was a gain in precision and reproducibility for all standards in the transition from Nuclisens 0.2 ml to Nuclisens Theoretically, the observed systematic decrease in results over the 2.5-year observation period for NASBA 0.1 ml may be an indication of the deterioration of the virus in the viral stock used for VQA standards over time. However, an internal VQA study to address this possibility found no indication of deterioration of the virus in quality assurance panels (3). The observed increase in the level of HIV-1 RNA over the 1-year observation period for NucliSens 1.0 ml also argues against deterioration of the virus in the viral stock. All statistically significant longitudinal trends were well within 2 SD, indicating no biologically relevant bias. We conclude that it is not necessary to make an intra-assay adjustment for time.
We have described the performance over a period spanning the introduction of HAART of three versions of OTC assays within an externally controlled multilaboratory program. NASBA technology is invariant to specimen type, an advantage that makes this assay valuable to clinicians and researchers testing nonplasma body fluids for HIV-1 RNA. Our data a SD were obtained separately for low-range and combined middle-and high-range results from each assay as the mean square errors from one-way analysis of variance.
b Adjusted for the laboratory. demonstrate that the precision of the OTC assays is comparable to that of other assays not invariant to specimen type. We also demonstrated that patient viral load levels in the HAART era can be measured with the same precision as or with better precision than in the pre-HAART era, despite an average HIV-1 RNA decrease of 2 log 10 units. We have shown that HIV-1 RNA measurements across multiple WIHS sites over a period of 4 years were comparable despite the introduction of HAART, different versions of the assay, and differences between labs.
Data in this manuscript were collected by the WIHS Collaborative Study Group, which is made up of the following consortia or centers 
